

Message from the Chairman

Development of New Drugs, Care for Life, Implementation of Governance, Pursuit of Sustainability

Microbio Co., Ltd. espouses the core values of “integrity, innovation, and love.” We forge partnerships with integrity, pioneer blue oceans through innovation, and give back to society with love. Under a steady business strategy, we have established a healthcare domain that encompasses the four dimensions of new drug development, medical-grade health supplements, investments in biotechnology, and organic products.

Our R&D and sales teams have entered the international market with diversified product strategies based on the exclusive anaerobic symbiosis fermentation technology to maximize the value of the microecological technology platform. We have obtained the drug license for our self-developed “MICRSOY oral solution” and continue to develop new indications. In 2024, in the international journal Gut Microbes, we announced that “MICRSOY oral solution” is able to enhance the anti-cancer effects of anti-PD-1 antibodies. In addition, we also obtained positive results on the unblinding of the exploratory clinical trial for late-stage non-small cell lung cancer completed at the end of the year. Microbio’s gut microbiome product Symbiota® also received the U.S. GRAS (Generally Recognized as Safe) Independent/Self-affirmed safety conclusion in 2024. This represents a significant step towards global market access for the Company’s products. Our subsidiary, Cotton Field Organic, focuses on organic and healthy brand value and aims to strengthen its omnichannel strategy (OMO, Online-Merge-Offline) by expanding its store network. As of 2024, it operated 80 stores.

We also continue to invest resources in promoting ESG to advance towards the sustainable vision of “Healthy Life and Sustainable Co-prosperity”. In 2022, we established the Sustainable Development Committee at the Board of Directors level in order to oversee matters and implementation outcomes related to the corporate governance, environmental sustainability, social inclusion and sustainable information disclosure, thereby driving ESG management in a top-down manner and further exceeding the requirements outlined in the Financial Supervisor Commission’s “Sustainable Development Roadmap” and “Sustainable Development Action Plan.” Starting from 2023, subsidiaries included in the consolidated financial statements have been included in the scope of greenhouse gas inventory and verification. In addition, carbon emissions have been reduced through the methods of energy-saving equipment procurement for production processes, products and offices. To enhance the credibility of sustainability information, we have commissioned an independent third-party organization to verify our sustainability report since 2022. Furthermore, in 2024, we also received the “Corporate Sustainability Report Golden Award” from the “Taiwan Sustainable Energy Research Foundation”. The incessant efforts of all staff members have been recognized with four consecutive rankings in the “top 5% of the TPEX-listed category” and our third consecutive listing in the top 10% of TWSE- or TPEX-listed companies in the “non-financial and non-electronics industry with a market capitalization over NT\$10 billion” of the annual Corporate Governance

Evaluations conducted by the Taiwan Stock Exchange Corporation (the results of the 11th evaluations were published by TWSE in May 2025), demonstrating Microbio’s remarkable achievements in corporate governance and sustainability.

With continuous R&D and innovation as its driving force, Microbio upholds the philosophy of ethical management and implements sustainable development while giving back to society. We aim to promote the development of innovative drugs globally, to expand preventive healthcare for sub-health conditions, to establish a high-quality, employee-focused enterprise, and to protect the sustainable global environment, thereby maximizing the corporate value and shareholder equity with best effort.

Microbio Co., Ltd.
Chairman

